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t-Butyl alcoholSprague–Dawley rats were exposed via inhalation to vapor condensates of either gasoline or gasoline
combined with various fuel oxygenates to assess potential neurotoxicity of evaporative emissions. Test
articles included vapor condensates prepared from ‘‘baseline gasoline’’ (BGVC), or gasoline combined
with methyl tertiary butyl ether (G/MTBE), ethyl t-butyl ether (G/ETBE), t-amyl methyl ether (G/TAME),
diisopropyl ether (G/DIPE), ethanol (G/EtOH), or t-butyl alcohol (G/TBA). Target concentrations were 0,
2000, 10,000 or 20,000 mg/mg3 and exposures were for 6 h/day, 5 days/week for 13 weeks. The func-
tional observation battery (FOB) with the addition of motor activity (MA) testing, hematoxylin and eosin
staining of brain tissue sections, and brain regional analysis of glial ﬁbrillary acidic protein (GFAP) were
used to assess behavioral changes, traditional neuropathology and astrogliosis, respectively. FOB and MA
data for all agents, except G/TBA, were negative. G/TBA behavioral effects resolved during recovery. Neu-
ropathology was negative for all groups. Analyses of GFAP revealed increases in multiplebrain regions lar-
gely limited to males of the G/EtOH group, ﬁndings indicative of minor gliosis, most signiﬁcantly in the
cerebellum. Small changes (both increases and decreases) in GFAP were observed for other test agents
but effects were not consistent across sex, brain region or exposure concentration.
 2014 Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/3.0/).1. Introduction
The 1990 amendments to the Clean Air Act (CAA) mandated the
use of oxygenates in motor gasoline. In 1994, the U.S. Environmen-
tal Protection Agency (EPA) issued a ﬁnal rule under the Act which
added new health effects information and testing requirements to
the Agency’s existing registration requirements. As described in
more detail in a companion paper (Henley et al., 2014), require-
ments include inhalation exposures to evaporative emissions of
the gasoline or additive in question. The health endpoints include
assessments for standard subchronic toxicity, neurotoxicity, geno-
toxicity, immunotoxicity, developmental and reproductive toxic-
ity, and chronic toxicity/carcinogenicity. The results of chronic
toxicity testing of gasoline and gasoline combined with MTBE havealready been reported (Benson et al., 2011). This paper describes
the results of neurotoxicity testing submitted to EPA.
Test materials evaluated in the 13 week toxicity studies
included vapor condensates prepared from an EPA described
‘‘baseline gasoline’’ (BGVC), as well as gasoline combined with
methyl tertiary butyl ether (G/MTBE), ethyl t-butyl ether
(G/ETBE), t-amyl methyl ether (G/TAME), diisopropyl ether
(G/DIPE), ethanol (G/EtOH), or t-butyl alcohol (G/TBA). The goal
of the studies was to provide information on the extent to which
the use of oxygenates in gasoline might alter the hazard of evap-
orative emissions that are encountered during refueling of vehi-
cles, compared to those from gasoline alone. The animals
evaluated for neurotoxicity were exposed concurrently with ani-
mals involved in a subchronic inhalation toxicity study of the
materials described above (Clark et al., 2014). Additional groups
of animals were exposed to the test materials concurrently to
evaluate the effects of exposure on immunotoxicity and genotox-
icity, the results of which are described elsewhere (White et al.,
2014; Schreiner et al., 2014).
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feature of all types of CNS damage. A hallmark of astrogliosis, often
termed ‘‘reactive gliosis,’’ is the intracellular accumulation of
astroglial ﬁlaments, the major protein component of which is glial
ﬁbrillary acidic protein (GFAP). Thus, an increase in the brain con-
centration of GFAP serves as a biochemical indicator of astrogliosis
and, as such, enhanced expression of GFAP is a biomarker of
neurotoxicity. To validate the use of GFAP as a biomarker of
neurotoxicity, prototype neurotoxicants were administered to
experimental animals and the effects of these agents on the tissue
content of GFAP was determined by immunoassay (O’Callaghan,
1991a, 2002; Norton et al., 1992; O’Callaghan and Sriram, 2005;
O’Callaghan et al., 2014). Assays of GFAP were found to reveal
dose-, time- and region-dependent patterns of neurotoxicity at
toxicant dosages below those that cause light microscopic evi-
dence of cell loss or damage (O’Callaghan, 1988; Norton et al.,
1992; O’Callaghan and Sriram, 2005; O’Callaghan et al., 2014).
Moreover, the temporal and regional increments in GFAP corre-
spond to the temporal and regional patterns of neuronal damage,
as revealed by sensitive silver stains (Balaban et al., 1988;
Balaban, 1992). These ﬁndings indicate that assaying brain regional
levels of GFAP represents a sensitive, simple and quantitative
approach for evaluation of nervous system damage (O’Callaghan,
1991a, 2000; Norton et al., 1992; O’Callaghan and Sriram, 2005).
In this study, both standard neurobehavioral and motor toxicity
assessments as well as the GFAP assay were used for assessing the
potential neurotoxic effects of the fuel vapors described above.
Although the EPA Guidelines for GFAP determination (US EPA,
1994a) speciﬁes six regions to be analyzed, the analysis used in
these studies was expanded to include an additional three areas
of the brain to maximize the potential for detecting enhanced
expression of GFAP due to exposure to the test substance.2. Methods and materials
2.1. Test material exposures
Seven separate inhalation studies involving exposures to vapor
condensates were conducted. Test materials included baseline
gasoline (BGVC) and BGVC combined with methyl t-butyl ether
(G/MTBE), ethanol (G/EtOH), t-amyl ethyl ether (G/TAME), ethyl
t-butyl ether (G/ETBE), diisopropyl ether (G/DIPE), or t-butyl
alcohol (G/TBA) at concentrations of 0, 2000, 10,000, 20,000 mg/
m3/day, 5 days a for a total of 65 exposures over 13 weeks, per-
formed at Huntingdon Life Sciences (East Millstone, NJ). Ten adult
Sprague–Dawley rats (5 males and 5 females) were used in each of
the investigations to examine neuropathology and to determine
changes in glial ﬁbrillary acidic protein (GFAP) levels in areas of
the brain. Motor activity and performance in the functional obser-
vational battery (FOB) was evaluated in all 20 animals. The animals
were satellite groups of a larger subchronic toxicity study, and the
generation and composition of the vapor concentrations as well as
additional details on the exposure methodology are reported in
companion articles (Henley et al., 2014; Clark et al., 2014).2.2. Neurobehavioral studies
FOB and motor activity evaluations were staggered over several
sessions and conducted on non-exposure days at least 16 h post-
exposure. With the exception of the pretest, evaluations were per-
formed ‘‘blind’’, i.e., the observer did not know the identity of the
animal’s exposure group. Evaluations were conducted once before
initiation of exposures and again during the 4th, 8th and 13th week
of exposures. Time of testing was balanced across treatment
groups. Noise level was maintained within a level of 55–65decibels by a white noise generator. Temperature, humidity and
illumination were measured and recorded to ensure that variations
in environmental conditions are minimal during all evaluations.
The functional observational battery (Moser, 1989) was performed
for all animals before evaluation of motor activity and included:
1. Home Cage Evaluations: posture, vocalization and palpebral
closure.
2. Handling Evaluations: reactivity to general stimuli
(handling); assessment of signs of autonomic function:
lacrimation, salivation, altered fur appearance, or red crusty
deposits around eyes.
3. Open Field Evaluations: arousal level and gait; count of
urination and defecation; convulsions, tremors, abnormal
movements or behaviors, excessive or repetitive actions;
piloerection and exophthalmos.
4. Reﬂex Assessments: response to visual (approach response)
and auditory (ﬁnger snap) stimuli; response to a tail pinch;
pupillary function.
5. Grip Strength (Meyer et al., 1979): grip strength was mea-
sured using a grip strength meter (Columbus Instruments
International Corporation, Columbus, Ohio).
6. Landing Foot Splay: each animal was dropped into a pan of
sand from a height of one foot. The distance between the
marks left by the hind paws was measured in centimeters.
7. Hind limb Extensor Strength: animals were held in a vertical
position facing the observer with a ﬁrm grasp around the
thorax. The observer placed one ﬁnger against the bottom
of each hind paw and pressed toward the animal. Muscular
resistance and pressure exerted by the animals were scored.
8. Air Righting Ability: animals were held upside down and
dropped from a height of one foot into a container of bed-
ding. The landing position of each animal was recorded.
9. Body Weight: animals were removed from their cages and
weighed using a Mettler Balance, Model PE4000 (Mettler
Instrument Corporation, Hightstown, New Jersey).
10. Motor Activity: using a modiﬁed version of Schulze’s proce-
dures (Schulze, 1990), the locomotor activity of all animals
was monitored using an automated Photobeam Activity
System (San Diego Instruments, Inc., San Diego, California).
Sessions were 60 min in length; each session was divided
into 12 intervals of 5 min.
2.3. Neuropathology
Following 13 weeks of exposures, designated animals (5/sex/
group) were anesthetized with an IP injection of sodium pentobar-
bital and transcardially perfused with phosphate buffered saline
followed by 1% glutaraldehyde and 4% paraformaldehyde in the
same buffer. After perfusion, the tissues listed in Table 1 were
obtained. Measurement of the size (length and width) and weight
of the whole brain (cerebrum, cerebellum and pons-medulla) were
made. All tissues were then placed into a fresh solution of the same
ﬁxative prior to processing.
Peripheral nerves were post-ﬁxed in 1% osmium tetroxide, pro-
cessed and embedded in epoxy resin, sectioned at approximately 2
microns and stained with toluidine blue. All other tissues, includ-
ing the brain, eye with optic nerve, spinal cord, trigeminal ganglia,
dorsal root ganglia, dorsal and ventral root ﬁbers, lungs and tra-
chea were processed by standard techniques, embedded in parafﬁn
and sectioned at approximately 6 microns.
The tissues listed in Table 1 were examined microscopically for
all animals as indicated. Tissues with macroscopic lesions were
examined in all animals. Any abnormalities not noted during
macroscopic postmortem examinations which were seen during
histological processing were recorded.
Table 1
Tissues examined microscopically.
No.a Tissues for neuropathology Exposure groups
Preserved Microscopic examination
All Control, high Low and mid
6 Brain (forebrain, central cerebrum, hippocampus, basal ganglia, midbrain, cerebellum and pons, medulla) X X
2 Eye with optic nerve X X
6 Spinal cord (cervical, thoracic, lumbar, cross and longitudinal sections) X X
2 Sciatic nerve (cross and longitudinal sections) X X
2 Tibial nerve (cross and longitudinal sections) X X
2 Sural nerve (cross and longitudinal sections) X X
2 Trigeminal ganglia X X
4 Dorsal root ganglia (from C3–C6 and L4–L6) X X
4 Dorsal root ﬁbers (from C3–C6 and L4–L6) X X
4 Ventral root ﬁbers (from C3-Cs and L4–L6) X X
6 Lungs and trachea X X X
Tissues with macroscopic ﬁndings X X X
a Number of organs/sections that were preserved/examined per animal.
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Personnel from the United States Center for Disease Control and
Prevention – NIOSH (CDC) Health Effects Laboratory Division sacri-
ﬁced (carbon dioxide inhalation) the animals (5 males, 5 females)
after the 13 week exposure period, and removed, weighed and dis-
sected the brains. The samples were shipped on dry ice to the CDC
Health Effects Laboratory, Morgantown, WV, and upon receipt,
were further processed for determination of GFAP response
according to EPA guidelines (US EPA, 1994a). Brains were dissected
free-hand on a cold plate. Analysis was limited to cerebellum, cor-
tex, hippocampus, hypothalamus, olfactory bulbs, pituitary, stria-
tum, thalamus and the rest of the brain. Each brain region was
homogenized in 10 volumes of hot (85–95 C) 1% sodium dodecyl
sulfate (SDS) and stored at 75 C until use. Total protein was
determined by the bicinchonic acid (BCA) method (Smith et al.,
1985) using bovine serum albumin as standard. GFAP was assayed
by detergent-based Sandwich ELISA (Enzyme-linked immunosor-
bant assay) employing the 96 well microplate format
(O’Callaghan, 1991a,b, 2002). This method is based on the binding
of GFAP to antibodies (i.e. rabbit anti-GFAP) that have been coated
onto individual wells of microtiter plates which is then bound in
‘‘sandwich’’ fashion by a second antibody to GFAP. The second anti-
body is bound by an enzyme-linked antibody directed toward it
but not toward the ﬁrst anti-GFAP antibody (i.e. monoclonal
anti-GFAP and alkaline phosphatase conjugated anti-mouse IgG).
Quantiﬁcation is achieved by addition of a substrate (i.e. p-nitro-
phenylphosphate) for the antibody bound enzyme, followed by
spectrophotometry of the colored reaction product using a micro-
titer plate reader. The amount of GFAP was expressed as lg GFAP/
mg total homogenate protein. The GFAP standard was prepared
from rat spinal cord as described previously (O’Callaghan, 1991a).2.5. Statistical analyses
The following parameters were analyzed statistically: mean
body weight values and body weight changes (from pretest), mean
motor activity counts, mean FOB data including forelimb and hind
limb grip strength measurements, and mean landing foot splay
measurements. In analyzing the FOB and motor activity data, all
analyses included sex as an independent variable. In those
instances where there were signiﬁcant effects of sex, separate anal-
yses by sex may have been done to explain the nature of the effect.
Some of the sensorimotor and observational battery variables
were measured on a continuous scale and some were measuredon a nominal or count scale. All measures were classiﬁed as either
continuous or nominal. The analysis of the continuous variables
was conducted by a mixed model analysis of covariance with a ﬁrst
order autoregressive error structure on the time points. The pretest
response was used as the covariate. The residuals from the model
were tested for normality at the p < 0.01 level of signiﬁcance. Those
variables that did not exhibit normally distributed residuals at the
0.01 level were transformed by Blom’s normalized rank transfor-
mation and reanalyzed (Blom, 1958). The nominal data of the func-
tional observational battery was analyzed by a cumulative logit
repeated measures analysis with contrast terms to test for differ-
ences between control and dosed groups (Agresti, 1989). For the
measures that were count data (such as number of rears or number
of urinations), the count responses may have been grouped into
several data ranges to allow sufﬁcient data in the cells. For exam-
ple, the count of urinations might have been separated into three
groups of 0, 1 to 4, 5 or more, and analyzed.
The analysis of the motor activity used a mixed model analysis
of covariance with an unstructured error relationship among the 5-
min periods, and a ﬁrst order autoregressive error structure on
weeks. The pretest response was used as the covariate. The resid-
uals from the model were tested for normality at the p < 0.01 level
of signiﬁcance by the Kolmogorov–Smirnov test for normality. If
the residuals were not normally distributed, the dependent vari-
able (number of beam breaks) was converted to a function of its
percentile rank, then transformed by the inverse normal distribu-
tion (the transformation is known as Blom’s transformation where
the rank order is replaced by [rank  0.375]/[n + 0.25]), and reana-
lyzed (Blom, 1958).
Statistical methods for the GFAP assay employed separate one-
way analysis of variance (ANOVA) for each of the brain areas from
male and female rats (JMP, SAS Institute, 1995). The signiﬁcance
level was set at p < 0.05 and, to ensure detection of between group
treatment effects, the least signiﬁcance-difference test (Keppel,
1973) was used for post hoc analyses.2.6. Compliance
These studies were conducted in accordance with the United
States Environmental Protection Agency’s (EPA) Good Laboratory
Practice Standards (US EPA, 1994b), and complied with all appro-
priate parts of the Animal Welfare Act Regulations USDA, 1989,
1991).The study also met the requirements of EPA’s guidelines
for neurotoxicity toxicity screening and GFAP determination (US
EPA, 1994a, 1994c, 1998).
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3.1. Motor activity
For the BGVC and G/MTBE exposure groups, the results of the
analyses do not indicate a statistically signiﬁcant exposure-related
effect for either the original data or the Blom transformed data and
the data plots do not suggest an exposure-related response (data
not shown).
G/EtOH and G/ETBE – the residuals from the motor activity data
analysis and those from the Blom transformed data were not
normally distributed. A possible explanation for the non-normal
distribution of the residuals is that approximately 32% of the
observations in the EtOH group and 19% in the G/ETBE group were
zero (due to acclimatization). It is difﬁcult to have normally
distributed residuals when a large percentage of the data have
the same value. However, inspection of the residuals shows a
reasonably symmetric distribution with slightly heavier tails than
a normal distribution. Overall, these departures of the residuals
from normality are not thought to affect the analysis conclusions
which do not indicate a statistically signiﬁcant exposure related
effect for either the original or Blom transformed data.
G/TAME – based on a preliminary non-statistical evaluation of
the data in which a possible increase in motor activity was noted
in the high dose females during the 4th and 13th week of exposure,
motor activity was also evaluated during the 17th week of study
(recovery). However, the subsequent statistical evaluation of the
data did not conﬁrm this initial determination. The results of the
analyses indicate a statistically signiﬁcant differences in response
by exposure, time, sex, exposure by sex by time interaction, and
exposure by time by replicate interaction for the Blom transformed
data (similar results were seen for the untransformed data).
In order to understand the interactions, analyses were per-
formed separately by sex. The residuals from the untransformed
data were not normally distributed for either sex. The residuals
Blom transformed analyses were normally distributed for themales
and not normally distributed for the residuals from the female anal-
ysis. There were no statistically signiﬁcant exposure related effects
for the data from the males. Analysis of the Blom transformed
female data indicated there was a statistically signiﬁcant exposure
related response with the high exposure group showingmore beam
breaks compared to the control group (p < 0.03). The least squares
means are the means accounting for the initial activity (pretest),
study week, replicates, and their interactions. There was no linear
relationship between exposure levels and response.
The residuals from the motor activity data analysis and those
from the Blom transformed data were not normally distributed.
Approximately 19% of the observations were zero. As explained
above for G/EtOH and G/ETBE, these departures of the residuals
from normality are not thought to affect the analysis conclusions.
G/DIPE – the results of the analysis of motor activity data indi-
cated statistically signiﬁcant differences in responses in exposure
levels for both the original data and the Blom transformed data
(p < 0.02). Speciﬁcally, contrast analysis of the Blom transformed
data showed that responses from low and medium exposure
groups were signiﬁcantly different from the control group. How-
ever, there was no linear relationship between exposure levels
and response, or any consistent change in activity related to expo-
sure. The data plots do not suggest a consistent exposure related
response, but show an increase in activity in the female control
group and a decrease in activity in the female mid exposure group
only during study week 4 (there was not a statistically signiﬁcant
time by exposure effect).
G/TBA – the results of the analyses indicated statistically
signiﬁcant differences in responses in exposure levels for boththe original data and the Blom transformed data (p < 0.01). Analy-
sis of contrast on Blom transformed data shows that the response
of high exposure group is signiﬁcantly more active compared to
the control group (p < 0.01).
Recovery – because only the control and high exposure groups
had recovery animals only these two groups were used in the
recovery analysis. The results indicated statistically signiﬁcant dif-
ferences in responses in exposure levels for both the original and
the Blom transformed data (p < 0.02 for original, and p < 0.05 for
the Blom transformed data). There were more beam breaks aver-
aged over time periods, sex, and replicates in the high exposure
group (mean = 54.71 breaks) compared to the control group
(mean = 50.33 breaks).
Overall, there was a statistically signiﬁcant increase in motor
activity seen in the high exposure G/TBA group relative to the con-
trol group during both the exposure and recovery periods.
3.2. Functional observational battery
3.2.1. Continuous measures
None of the four continuous measures in the FOB (i.e., fore- and
hindlimb grip strength, foot splay, and body weight) indicated sta-
tistically signiﬁcant exposure-related differences in any of the
seven exposure groups. The residuals from body weight were not
normally distributed (neither the observed data nor Blom trans-
formed data) in most of the exposure groups (Table 2). Because
the signiﬁcant levels were not near the 0.05 level of signiﬁcance
the deviation from normality was not considered crucial in these
analyses.
In the G/TBA group, analysis of Blom transformed foot splay
data indicated a signiﬁcant exposure by time interaction
(p < 0.04). Contrast analysis on Blom transformed data of foot splay
indicated the week 4 to week 8 mean response of the control group
was signiﬁcantly different from the corresponding change in the
mid dose group. A reasonable interpretation is that the week 8 con-
trol exposure group mean landing foot splay is higher than
expected.
3.2.2. Discrete measures
For the measures evaluated in the FOB on a nominal or count
scale, only between 6 and 11 of the measures showed any practical
level of variation in the seven exposure groups (Table 2). None of
these demonstrated statistically signiﬁcant exposure-related dif-
ferences. For the remaining variables all animals, or at most three
to four responses, showed the same response in all groups at all
time points and were not analyzed because of the lack of meaning-
ful variation in response.
3.3. Brain measurements
No toxicologically signiﬁcant differences in brain measure-
ments or weights were observed in any of the test substance
exposed animals in any of the exposure groups. A statistically sig-
niﬁcant decrease in brain weight was noted in the high dose male
BGVC animals at the terminal interval. However, a similar differ-
ence was not seen at the same interval in the main study animals
(Clark et al., 2014) and this difference was not considered toxico-
logically signiﬁcant. The brain weights in perfused neuropathology
animals were lower in general than those in non-perfused main
study animals since the perfusion ﬁxatives desiccate the brain
tissue.
3.4. Neuropathology
No microscopic changes attributable to test substance effect
were observed in brain, spinal cord, eyes, peripheral nerves, or
Table 2
Functional observational battery (FOB) ﬁndings.
FOB areas and measures Exposure group
BGVC G/MTBE G/EtOH G/TAME G/ETBE G/DIPE G/TBA
Home cage evaluations
Posture vocalization X X X X X X X
Palpebral closure X X X X
Handling evaluations
Ease of removal X X X X X
Ease of handling X X
Chromodacryorrhea X X X X
Lacrimation X X
Salivation
Altered fur appearance
Open ﬁeld evaluations
Gait and posture
Locomotion X X X
Arousal level X X X
Exophthalmia
Piloerection X X
Defecation count X X X X X X X
Urination count X X X X X X X
Fasciculation
Tremors
Convulsions
Reﬂex assessments
Response to visual stimuli X X X X X
Response to auditory stimuli
Pain perception X X
Pupillary response X X
Sensitivity to light touch X X X X X X
Proprioception
Other
Forelimb grip strength* O
Hindlimb grip strength* O,B
Air righting ability
Landing foot splay* B
Body weight* O, B O, B O, B O, B O O, B
X – demonstrated non-statistically signiﬁcant variation.
O = observed data not normally distributed; B = Blom transformed data not normally distributed.
A blank box indicates there was not a statistically signiﬁcant exposure-related difference in the endpoint evaluated.
* Analyzed as a continuous variable.
Table 3
Mean GFAP levels on speciﬁc regions of rat brains following a 13 week whole body
inhalation exposure to baseline gasoline (BGVC) vapor condensate.
Brain area Control 2000 mg/m3 10,000 mg/m3 20,0000 mg/m3
Males (N = 5)
Striatum 1.01 ± 0.09a 0.89 ± 0.18 0.84 ± 0.17 0.93 ± 0.09
Hippocampus 2.88 ± 0.24 3.08 ± 0.27 2.63 ± 0.21 2.76 ± 0.12
Cortex 1.31 ± 0.14 1.44 ± 0.07 1.43 ± 0.13 1.20 ± 0.06
Olfactory bulb 2.49 ± 0.21 2.73 ± 0.47 2.26 ± 0.23 2.36 ± 0.12
Thalamus 2.15 ± 0.23 2.17 ± 0.29 1.71 ± 0.19 1.88 ± 0.10
Hypothalamus 8.62 ± 0.81 7.46 ± 0.84 6.82 ± 0.74 6.66 ± 0.90
Cerebellum 4.63 ± 0.37 4.09 ± 0.49 3.72 ± 0.28 3.93 ± 0.25
Rest of brain 4.70 ± 0.34 5.48 ± 0.58 3.81 ± 0.39 5.11 ± 0.38
Females (N = 5)
Striatum 0.90 ± 0.13 0.82 ± 0.05 0.95 ± 0.04 0.87 ± 0.11
Hippocampus 2.83 ± 0.18 2.46 ± 0.06 3.06 ± 0.20 2.89 ± 0.36
Cortex 1.57 ± 0.14 1.50 ± 0.12 1.84 ± 0.28 1.60 ± 0.22
Olfactory bulb 2.34 ± 0.26 2.49 ± 0.28 2.70 ± 0.27 2.50 ± 0.26
Thalamus 2.12 ± 0.23 1.64 ± 0.12 2.02 ± 0.23 1.88 ± 0.23
Hypothalamus 8.71 ± 0.90 6.13 ± 0.36 8.36 ± 1.30 7.71 ± 0.90
Cerebellum 3.98 ± 0.36 3.04 ± 0.35 4.29 ± 0.54 4.23 ± 0.40
Rest of brain 4.59 ± 0.37 4.87 ± 0.23 4.93 ± 0.30 4.91 ± 0.37
a Each value represents the mean ± SEM for the concentration of GFAP (lg/mg
total protein).
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exposure studies.
3.5. GFAP results
Results of the GFAP analyses are presented in a series of tables
and ﬁgures. Table 3 presents GFAP levels from BGVC-exposed ani-
mals and serves as a baseline comparison for the other exposure
groups. GFAP levels from the gasoline–ether and gasoline–alcohol
exposed animals are shown in Table 4 (G/MTBE), Table 5
(G/TBA), Table 6 (G/ETBE), and Table 7 (G/EtOH), respectively. Con-
trol levels for GFAP vary markedly across different brain regions
seen historically (Fig. 1) and in the present studies. Mean GFAP
levels were reported for striatum, hippocampus, olfactory bulb,
thalamus, hypothalamus, cerebellum, and the rest of the brain.
Assays of pituitary samples gave variable results for BGVC and
G/MTBE and were generally below levels of detection by this
method for other vapor condensate samples and thus are not reported.
Exposure to BGVC (Table 3) G/DIPE and G/TAME did not elevate
GFAP levels in any brain region above controls in male or female
rats.
Exposure to G/MTBE (Table 4) caused slight statistically signif-
icant increases in GFAP levels in the hippocampus in male rats of
the 2000 mg/m3 group and in the rest of the brain in male rats in
the 2000 mg/m3 and 10,000 mg/mg3 group. Increases in GFAP in
the thalamus were also seen in 2000 mg/m3 exposed females.
Effects were small in magnitude and not concentration-related.G/TBA (Table 5) exposed male rats had a slight statistically
signiﬁcant increase in GFAP in the cortex of the 2000 mg/m3 group
Table 4
Mean GFAP levels on speciﬁc regions of rat brains following a 13 week whole body
inhalation exposure to gasoline MTBE (G/MTBE) vapor condensate.
Brain areaA1:E20 Control 2000 mg/m3 10,000 mg/m3 20,0000 mg/m3
Males (N = 5)
Striatum 0.94 ± 0.14a 0.97 ± 0.13 1.08 ± 0.16 0.83 ± 0.07
Hippocampus 2.62 ± 0.23 3.45 ± 0.30b 3.18 ± 0.28 3.02 ± 0.12
Cortex 1.37 ± 0.06 1.66 ± 0.20 1.65 ± 0.10 1.28 ± 0.11
Olfactory bulb 2.14 ± 0.14 2.45 ± 0.23 2.06 ± 0.17 2.36 ± 0.15
Thalamus 1.90 ± 0.08 2.19 ± 0.20 2.04 ± 0.08 2.13 ± 0.08
Hypothalamus 6.04 ± 0.99 6.64 ± 0.93 6.63 ± 0.79 6.09 ± 0.71
Cerebellum 5.97 ± 0.17 6.53 ± 0.38 5.99 ± 0.56 6.23 ± 0.43
Rest of brain 4.19 ± 0.42 5.81 ± 0.51b 5.58 ± 0.27b 5.08 ± 0.49
Females (N = 5)
Striatum 0.93 ± 0.06 0.96 ± 0.09 0.83 ± 0.06 0.78 ± 0.05
Hippocampus 2.67 ± 0.08 3.12 ± 0.20 2.64 ± 0.16 2.60 ± 0.14
Cortex 1.23 ± 0.05 1.26 ± 0.10 1.18 ± 0.10 1.04 ± 0.07
Olfactory bulb 1.91 ± 0.16 1.92 ± 0.16 2.01 ± 0.09 2.01 ± 0.15
Thalamus 1.58 ± 0.13 1.96 ± 0.25b 1.64 ± 0.08 1.43 ± 0.06
Hypothalamus 5.67 ± 0.65 6.59 ± 0.61 4.86 ± 0.11 5.08 ± 0.52
Cerebellum 5.22 ± 0.49 5.18 ± 0.78 4.94 ± 0.26 4.16 ± 0.36
Rest of brain 4.62 ± 0.51 4.54 ± 0.30 4.04 ± 0.22 4.29 ± 0.26
a Each value represents the mean ± SEM for the concentration of GFAP (lg/mg
total protein).
b Statistically different from control (p < 0.05).
Table 5
Mean GFAP levels on speciﬁc regions of rat brains following a 13 week whole body
inhalation exposure to gasoline TBA (G/TBA) vapor condensate.
Brain area Control 2000 mg/m3 10,000 mg/m3 20,0000 mg/m3
Males (N = 5)
Striatum 1.22 ± 0.12a 1.25 ± 0.12 1.18 ± 0.07 1.32 ± 0.10
Hippocampus 2.52 ± 0.17 2.76 ± 0.18 3.00 ± 0.30 2.62 ± 0.07
Cortex 1.17 ± 0.07 1.42 ± 0.10b 1.23 ± 0.13 1.10 ± 0.06
Olfactory bulb 2.12 ± 0.21 2.11 ± 0.18 1.92 ± 0.19 2.28 ± 0.20
Thalamus 2.29 ± 0.11 2.73 ± 0.38 2.18 ± 0.22 2.30 ± 0.15
Hypothalamus 7.08 ± 0.70 7.40 ± 0.96 6.48 ± 0.45 4.97 ± 0.70b;
Cerebellum 5.21 ± 0.47 4.66 ± 0.22 4.93 ± 0.44 4.67 ± 0.34
Rest of brain 4.91 ± 0.33 5.17 ± 0.43 4.45 ± 0.20 4.09 ± 0.16
Females (N = 5)
Striatum 1.32 ± 0.20 1.47 ± 0.12 1.41 ± 0.10 1.05 ± 0.11
Hippocampus 2.72 ± 0.12 2.74 ± 0.07 2.87 ± 0.18 2.36 ± 0.22
Cortex 1.17 ± 0.06 1.22 ± 0.07 1.37 ± 0.07 1.12 ± 0.06
Olfactory bulb 1.80 ± 0.24 1.91 ± 0.10 2.07 ± 0.17 1.80 ± 0.07
Thalamus 2.16 ± 0.15 2.08 ± 0.07 2.49 ± 0.12 1.96 ± 0.12
Hypothalamus 7.01 ± 0.72 6.27 ± 0.75 6.05 ± 0.47 5.18 ± 0.53
Cerebellum 3.96 ± 0.12 4.42 ± 0.34 4.81 ± 0.22 3.96 ± 0.22
Rest of brain 4.51 ± 0.32 5.00 ± 0.65 5.18 ± 0.33 3.95 ± 0.12
a Each value represents the mean ± SEM for the concentration of GFAP (lg/mg
total protein).
b Statistically different from control (p < 0.05).
Table 6
Mean GFAP levels on speciﬁc regions of rat brains following a 13 week whole body
inhalation exposure to gasoline ETBE (G/ETBE) vapor condensate.
Brain area Control 2000 mg/m3 10,000 mg/m3 20,0000 mg/m3
Males (N = 5)
Striatum 1.04 ± 0.11a 0.82 ± 0.07 1.01 ± 0.05 0.93 ± 0.07
Hippocampus 2.43 ± 0.15 2.32 ± 0.08 2.26 ± 0.23 2.45 ± 0.09
Cortex 2.15 ± 0.12 1.75 ± 0.11b; 1.88 ± 0.11 1.72 ± 0.07b;
Olfactory bulb 2.21 ± 0.15 2.04 ± 0.15 2.22 ± 0.13 2.26 ± 0.16
Thalamus 2.76 ± 0.29 2.18 ± 0.13 2.67 ± 0.12 2.40 ± 0.17
Hypothalamus 7.12 ± 0.95 8.17 ± 1.45 9.49 ± 1.82 6.54 ± 0.93
Cerebellum 4.78 ± 0.32 4.11 ± 0.30 4.28 ± 0.27 4.11 ± 0.36
Rest of brain 6.46 ± 0.84 4.91 ± 0.28b; 5.61 ± 0.32 5.36 ± 0.37
Females (N = 5)
Striatum 0.88 ± 0.06 1.12 ± 0.07b 0.99 ± 0.09 1.05 ± 0.12
Hippocampus 2.33 ± 0.16 2.69 ± 0.33 2.36 ± 0.20 2.24 ± 0.10
Cortex 1.77 ± 0.09 1.98 ± 0.13 1.75 ± 0.17 1.76 ± 0.06
Olfactory bulb 2.04 ± 0.17 2.43 ± 0.21 2.30 ± 0.30 2.33 ± 0.08
Thalamus 1.95 ± 0.15 2.41 ± 0.22 2.37 ± 0.30 2.24 ± 0.17
Hypothalamus 4.89 ± 1.06 7.21 ± 0.69 8.50 ± 1.54 7.50 ± 1.58
Cerebellum 4.02 ± 0.37 4.44 ± 0.18 4.41; ± 0.51 4.25 ± 0.32
Rest of brain 4.61 ± 0.23 6.17 ± 0.23b 5.18 ± 0.58 5.73 ± 0.43
a Each value represents the mean ± SEM for the concentration of GFAP (lg/mg
total protein).
b Statistically different from control (p < 0.05).
Table 7
Mean GFAP levels on speciﬁc regions of rat brains following a 13 week whole body
inhalation exposure to gasoline ethanol (G/EtOH) vapor condensate.
Brain area Control 2000 mg/m3 10,000 mg/m3 20,0000 mg/m3
Males (N = 5)
Striatum 0.94 ± 0.10a 1.28 ± 0.18 1.44 ± 0.29b 1.10 ± 0.14
Hippocampus 2.91 ± 0.15 3.46 ± 0.39 3.40 ± 0.31 2.91 ± 0.14
Cortex 1.06 ± 0.07 1.40 ± 0.12b 1.33 ± 0.12 1.18 ± 0.08
Olfactory bulb 2.28 ± 0.13 3.03 ± 0.36b 2.88 ± 0.15 2.48 ± 0.22
Thalamus 1.53 ± 0.09 2.30 ± 0.18b 1.97 ± 0.30b 1.73 ± 0.14
Hypothalamus 7.52 ± 1.03 8.53 ± 0.27 7.34 ± 0.78 7.44 ± 1.09
Cerebellum 3.49 ± 0.14 4.52 ± 0.25b 4.62 ± 0.36b 4.42 ± 0.32b
Rest of brain 3.53 ± 0.27 4.54 ± 0.51b 3.92 ± 0.19 3.89 ± 0.32
Females (N = 5)
Striatum 0.94 ± 0.12 1.24 ± 0.19 1.00 ± 0.09 1.04 ± 0.14
Hippocampus 2.76 ± 0.13 3.13 ± 0.13 2.91 ± 0.21 2.90 ± 0.21
Cortex 1.10 ± 0.06 1.26 ± 0.15 1.13 ± 0.08 1.16 ± 0.10
Olfactory bulb 2.57 ± 0.15 3.15 ± 0.31 2.53 ± 0.26 2.96 ± 0.19
Thalamus 1.54 ± 0.09 1.61 ± 0.14 1.77 ± 0.12 1.57 ± 0.06
Hypothalamus 7.34 ± 0.73 8.21 ± 1.03 9.62 ± 1.05 8.48 ± 0.44
Cerebellum 3.65 ± 0.15 3.93 ± 0.22 4.17 ± 0.34 3.97 ± 0.41
Rest of brain 3.65 ± 0.13 3.92 ± 0.44 3.92 ± 0.29 3.91 ± 0.31
a Each value represents the mean ± SEM for the concentration of GFAP (lg/mg
total protein).
b Statistically different from control (p < 0.05).
Fig. 1. Levels of GFAP found in different regions of rat brain. OB, olfactory bulbs; Str,
striatum; Hip, hippocampus; Hypo, hypothalamus; Ctx. Cortex; Cbm, cerebellum;
BS, brain stem. Adapted from Martin and O’Callaghan, 1995.
S40 J.P. O’Callaghan et al. / Regulatory Toxicology and Pharmacology 70 (2014) S35–S42and a decrease in GFAP in the hypothalamus of 20,000 mg/m3
males.
No changes in GFAP levels were seen in females. G/ETBE expo-
sure (Table 6) was associated with slight statistically signiﬁcant
decreases in GFAP levels in the cortex of males in the 2000 and
20,000 mg/m3 groups and rest of the brain in 2000 mg/m3 males.
Slight statistically signiﬁcant increases in GFAP levels were seen
in 2000 mg/m3 females in the striatum and rest of the brain. The
increases in the striatum of females at the lowest concentration
were small in magnitude.
Statistically signiﬁcant changes in GFAP levels were seen in
male rats exposed to G/EtOH (Table 7, Fig. 2). In the cerebellum
statistically signiﬁcant increases in GFAP were seen at all dose lev-
els although at the highest concentration (20,000 mg/m3) the
increase was below that seen at lower dose levels. GFAP increases
in the thalamus were statistically signiﬁcant but not concentration
related at 2000 and 10,000 mg/m3 and increases were seen only at
Fig. 2. Levels of GFAP found in different regions of rat brain for rats treated with
EtOH. Str: striatum; Hip: hippocampus; Ctx: cortex; OB: olfactory bulbs; TH:
thalamus; Hyp: hypothalamus; Cb: cerebellum; RoB: rest of brain. Each value
represents the mean ± SEM for the concentration of GFAP (lg/mg total protein).
⁄Statistically different from air control, p < 0.05.
J.P. O’Callaghan et al. / Regulatory Toxicology and Pharmacology 70 (2014) S35–S42 S412000 mg/m3 in the cortex, olfactory bulbs and the rest of the brain
and only in the striatum in the 10,000 mg/m3 group where the
increase was 150% of control. None of the G/EtOH exposed females
showed statistically signiﬁcantly increases in GFAP in any brain
area.
4. Conclusions and discussion
Overall, administration of the gasoline substances at the con-
centrations tested were not associated with changes in motor
activity or with any change in counts of the 25 nominal FOB mea-
sures, or the 4 continuous FOB measures. The foot splay differences
in the G/TBA group occurred within an interaction and did not
appear to be part of an exposure related change.
Three of the test materials (BGVC, G/DIPE and G/TAME) showed
no statistically signiﬁcant increases in GFAP levels in male or
female rats. Under the exposure conditions employed, treatment-
induced astrogliosis i.e. an induction in brain region levels of GFAP,
did not occur in the representative areas of the adult rat brain for
these materials. When male rats showed statistically signiﬁcant
changes in various brain regions, effects in females exposed to
the same materials were either not present (G/TBA, G/EtOH) or
minimal and not-concentration related (G/MTBE, G/ETBE).
Decreases in GFAP levels seen in a few regions in male rats (G/
TBA, G/ETBE) were not interpreted as adverse because the neuro-
toxicological signiﬁcance of a decrease in GFAP is unknown. For
these gasoline/oxygenate blend vapor condensates exposure by
inhalation for 13 weeks did not appear to result in toxicologically
signiﬁcant gliosis in the brain regions examined. Statistical differ-
ences observed in males and females were attributed to non-con-
centration related variations in response and in some cases
inconsistent dissection of difﬁcult brain regions.
The exception is response of rats exposed to G/EtOH. Increases
in GFAP levels were seen in several brain regions in male rats with
a concentration-related increase seen over all doses in the cerebel-
lum although the high dose dropped back below the increases at
lower dose levels. These increases in the cerebellum were in the
30% range and indicated minor gliosis This ﬁnding is consistent
with positive GFAP results reported from oral treatment of ethanol
alone (Franke et al., 1997).It can be concluded that inhalation exposures for 13 weeks to
gasoline vapors and vapors from gasoline combined with the fuel
oxygenates studied is largely without effect on morphological,
functional and biochemical indices of neurotoxicity. Although
some changes in GFAP levels were reported, in general, neuropa-
thologically relevant induction of astrogliosis was not observed.
Induction of the expression of GFAP reveals underlying neuropa-
thology regardless of the cause, dose or location of the damage
to the CNS (O’Callaghan and Sriram, 2005). Only the G/EtOH results
were considered indicative of compound induced gliosis damage
which was not reﬂected in neurobehavioral or neuropathologic
study results. Even in this case, however, the levels of GFAP
observed were barely above baseline and did not approach values
for known neurotoxicants that produce only subtle damage to the
affected brain area (e.g. see O’Callaghan and Sriram, 2005;
O’Callaghan et al., 2014). Thus, while the current data on G/EtOH
are of note, they deserve a more comprehensive evaluation and
validation in future studies.
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